 Clinical Study
August 21, 2024
In recent developments within the biotech industry, Oragenics Inc. has made strides in its commitment to addressing concussions, a significant public health issue. The company has announced the completion of spray-dry drug manufacturing and the filling of intranasal devices, positioning itself for a Phase IIa clinic...
|
Partnership
August 21, 2024
In an era where technological integration is paramount, iCoreConnect, Inc. is making a significant move in the dental sector. The recent announcement of a partnership with DSO MarketWatch a recognized leader in business intelligence for the dental industry highlights iCoreConnect’s strategy to strengthen its footh...
|
Product Service News
August 21, 2024
In a notable development for e-commerce businesses, Bridgeline Digital Inc. has introduced an innovative multi-site management feature for its HawkSearch platform. This new capability is poised to streamline search and navigation across multiple websites, providing users an efficient and cohesive experience. As onli...
|
|
 Business Update
August 21, 2024
Arrowhead Pharmaceuticals Advances RNAi Therapeutics: New Phase 3 Data, Obesity Candidates, and Strategic FinancingArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) continues to drive innovation in the realm of RNA interference (RNAi) therapeutics, with significant developments anticipated at the upcoming European Soc...
 Partnership
August 21, 2024
In a significant move that could transform the landscape of cognitive disorder diagnosis and management, Firefly Neuroscience has announced a strategic partnership with Neurology Consultants of Dallas (NCD). This collaboration aims to enhance early detection efforts and improve patient outcomes through innovative br...
|
|
Our most Popular Articles
|
Announcement
October 14, 2024
VEON Launches KINOM Digital Entertainment Platform in Uzbekistan Amsterdam and Tashkent, 9 October 2024 VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON), a global digital operator, has announced the official launch of its new digital entertainment platform, KINOM, in Uzbekistan. This strategic move marks a signi...
|
Announcement
December 4, 2024
In an era defined by rapid technological evolution, two pioneering companies are making significant strides within the realms of satellite communications and Internet of Things (IoT) innovations. WISeSat.Space is advancing its ambitious project to establish a European Low Earth Orbit (LEO) satellite constellation wh...
|
Product Service News
September 11, 2024
In the realm of contemporary medical innovation, Aclarion Inc. has recently unfolded a pivotal chapter within its ambitious LIFEHAB trial. The company has taken significant strides by successfully conducting its inaugural Nociscan examinations, aimed at elucidating the intricate relationship between biomarkers locat...
|
|
|
Company News
|
Partnership
August 21, 2024
In an era where technological integration is paramount, iCoreConnect, Inc. is making a significant move in the dental sector. The recent announcement of a partnership with DSO MarketWatch a recognized leader in business intelligence for the dental industry highlights iCoreConnect’s strategy to strengthen its footh...
|
Product Service News
August 21, 2024
In a notable development for e-commerce businesses, Bridgeline Digital Inc. has introduced an innovative multi-site management feature for its HawkSearch platform. This new capability is poised to streamline search and navigation across multiple websites, providing users an efficient and cohesive experience. As onli...
|
Product Service News
August 21, 2024
In a bold stride towards transforming drug testing practices, Intelligent Bio Solutions Inc. (NASDAQ: INBS) has proudly announced a major milestone: the installation of over 1,000 Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024. This remarkable achievement not only highlights the company’s in...
|
|
|
Company News
 Clinical Study
August 21, 2024
|
Company News
 Clinical Study
August 21, 2024
|
Company News
 Announcement
August 21, 2024
|
More Company News
|
Product Service News
August 21, 2024
|
Product Service News
August 21, 2024
|
Product Service News
August 21, 2024
|
Management Changes
August 21, 2024
|
Product Service News
August 21, 2024
|
Clinical Study
Radiopharmaceutical Revolution: Monopar Therapeutics' Multi-Faceted Approach in Targeting Advanced Cancers
Monopar Therapeutics Inc. (Nasdaq: MNPR), a pioneering clinical-stage radiopharmaceutical company, has embarked on an exciting journey to bring innovative treatments to cancer patients. The company is making waves with its novel radiopharmaceuticals, MNPR-101-Lu and MNPR-101-Zr, designed to revolutionize cancer therapy and diagnostic imaging. This article delves into Monopar's recent advancements, emphasizing the clearance for a Phase 1 therapeutic trial of MNPR-101-Lu, the first-in-human Phase 1 trial enrollment for MNPR-101-Zr, and the recognition of their work at the upcoming European Association of Nuclear Medicine (EANM) 2024 Annual Congress.
Groundbreaking Clearance to Proceed with Phase 1 Trial of MNPR-101-Lu
On August 21, 2024, Monopar announced a significant milestone: the Human Research Ethics Committee (HREC) in Australia granted clearance to initiate a Phase 1 therapeutic trial for MNPR-101-Lu in patients with advanced cancers. This novel radiopharmaceutical combines Monopar's proprietary antibody MNPR-101, which targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177 (Lu-177). This development underscores Monopar’s commitment to advancing cancer treatment through precision medicine.
The Phase 1 trial aims to evaluate the safety, tolerability, and initial efficacy of MNPR-101-Lu in humans. Given the innovative mechanism of action, whereby the antibody selectively binds to uPAR a receptor abundantly expressed in various aggressive tumors MNPR-101-Lu holds significant potential to selectively deliver the radioactive payload to tumor cells, minimizing collateral damage to healthy tissues.
First Patient Enrolled in the Phase 1 Dosimetry and Imaging Trial of MNPR-101-Zr
Following the HREC clearance, Monopar's momentum continued with another landmark achievement. On July 9, 2024, the company announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging clinical trial of MNPR-101-Zr. This novel imaging agent is a combination of Monopar's MNPR-101 antibody and the radioisotope zirconium-89 (Zr-89).
The primary of this trial is to understand the dosimetry and biodistribution of MNPR-101-Zr in patients, hence providing crucial insights into the optimal dosing strategies and therapeutic potential of the antibody. Imaging with Zr-89 allows researchers to visualize and track the distribution of MNPR-101 within the body using positron emission tomography (PET). This information will guide the subsequent development stages of therapeutic versions of MNPR-101, such as MNPR-101-Lu.
Global Recognition at EANM 2024
Monopar’s innovative research has not gone unnoticed in the scientific community. On June 25, 2024, it was announced that an abstract
August 21, 2024
|
Product Service News
August 21, 2024
|
Product Service News
August 21, 2024
|
Stocks on the Move
August 21, 2024
|
Stocks on the Move
August 21, 2024
|
|
|
|
Related News
|
Stocks on the Move
|
Stocks on the Move
|
|
Stocks
|
Stocks on the Move
|
Product Service News
|
Clinical Study
|
|
|
|
Business News
|
|
Business Update
Arrowhead Pharmaceuticals Advances RNAi Therapeutics: New Phase 3 Data, Obesity Candidates, and Strategic FinancingArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) continues to drive innovation in the realm of RNA interference (RNAi) therapeutics, with significant developments anticipated at the upcoming European Soc...
|
|
Partnership
In a significant move that could transform the landscape of cognitive disorder diagnosis and management, Firefly Neuroscience has announced a strategic partnership with Neurology Consultants of Dallas (NCD). This collaboration aims to enhance early detection efforts and improve patient outcomes through innovative br...
|
 Product Service News
In a remarkable achievement for community health, Salinas, California, has become the first certified Blue Zones Community in Monterey County. This certification signifies that the city has successfully met and exceeded its phase one well-being transformation goals as part of the Blue Zones Project a strategic initi...
|
 Product Service News
SAN DIEGO, Aug. 21, 2024 In a strategic move to bolster its wealth management capabilities, LPL Financial LLC (Nasdaq: LPLA) proudly announced today the addition of over 30 financial advisors from Academy Financial, Inc. and PFG Advisors to its broker-dealer, registered investment adviser (RIA), and custodial pla...
|
 Clinical Study
In recent developments within the biotech industry, Oragenics Inc. has made strides in its commitment to addressing concussions, a significant public health issue. The company has announced the completion of spray-dry drug manufacturing and the filling of intranasal devices, positioning itself for a Phase IIa clinic...
|
Our Most Popular Articles
|
 Announcement
VEON Launches KINOM Digital Entertainment Platform in Uzbekistan Amsterdam and Tashkent, 9 October 2024 VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON), a global digital operator, has announced the official launch of its new digital entertainment platform, KINOM, in Uzbekistan. This strategic move marks a signi...
|
 Announcement
In an era defined by rapid technological evolution, two pioneering companies are making significant strides within the realms of satellite communications and Internet of Things (IoT) innovations. WISeSat.Space is advancing its ambitious project to establish a European Low Earth Orbit (LEO) satellite constellation wh...
|
 Product Service News
In the realm of contemporary medical innovation, Aclarion Inc. has recently unfolded a pivotal chapter within its ambitious LIFEHAB trial. The company has taken significant strides by successfully conducting its inaugural Nociscan examinations, aimed at elucidating the intricate relationship between biomarkers locat...
|
More News
|
 Partnership
In an era where technological integration is paramount, iCoreConnect, Inc. is making a significant move in the dental sector. The recent announcement of a partnership with DSO MarketWatch a recognized leader in business intelligence for the dental industry highlights iCoreConnect’s strategy to strengthen its footh...
|
 Product Service News
In a notable development for e-commerce businesses, Bridgeline Digital Inc. has introduced an innovative multi-site management feature for its HawkSearch platform. This new capability is poised to streamline search and navigation across multiple websites, providing users an efficient and cohesive experience. As onli...
|
 Product Service News
In a bold stride towards transforming drug testing practices, Intelligent Bio Solutions Inc. (NASDAQ: INBS) has proudly announced a major milestone: the installation of over 1,000 Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024. This remarkable achievement not only highlights the company’s in...
|
 Clinical Study
: The PainReform Bunionectomy Study offers significant insights into the management of post-operative pain through a novel delivery method of PRF-110. This article reviews the study findings, comparing traditional pain management approaches with the innovative PRF-110 delivery system, and discusses the implications ...
|
 Clinical Study
Atossa Therapeutics, in collaboration with Quantum Leap Healthcare Collaborative, has initiated a groundbreaking clinical trial, the I-SPY 2 study, to evaluate the neoadjuvant potential of (Z)-endoxifen in combination with the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib for patients diagnosed with es...
|
 Announcement
Beijing, China - August 21, 2024 - Kuke Music Holding Limited (NYSE: KUKE), a leading classical music service platform in China, has officially announced that it will hold its Annual General Meeting (AGM) and a subsequent Class Meeting on September 20, 2024. The AGM is scheduled to commence at 10:30 a.m. Beijing tim...
|
 Product Service News
As the NFL gears up for another action-packed season, a striking new report from Vivid Seats sheds light on the passionate allegiances that define American football culture. The 2024 NFL Fan Loyalty Report reveals a fascinating landscape of team devotion, highlighting which franchises enjoy the most robust following...
|
 Product Service News
GDC Launches TikTok Account to Share Latest AI-Related News and TrendsIn a groundbreaking move set to shake up the landscape of artificial intelligence content, GD Culture Group Limited (GDC), alongside its subsidiary AI Catalysis Corp., today announced the launch of its TikTok account, @streamlineainews. This init...
|
 Product Service News
Nanox Secures FDA Clearance for HealthCCSng V2.0, Enhancing AI Capability in Cardiovascular AssessmentNanox, a medical imaging technology company, has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its upgraded advanced AI cardiac solution, HealthCCSng V2.0. This new v...
|
 Management Changes
Expansion of leadership team to strengthen global clinical expertise
Tempest Therapeutics Inc, a leading healthcare company, has recently appointed Troy M. Wagner as its new Vice President of Quality Assurance. This strategic move aims to expand the company s leadership team and further enhance its global c...
|
 Product Service News
AUGUST 21, 2024 NEW YORK In a most enlightening communique, Diamond Equity Research, a preeminent establishment dedicated to the rigorous investigation of enterprises of modest capitalization, hath issued an update pertaining to the fiscal standing of uCloudlink Group Inc. (NASDAQ: UCL). This disclosure elucida...
|
Clinical Study
Radiopharmaceutical Revolution: Monopar Therapeutics' Multi-Faceted Approach in Targeting Advanced Cancers
Monopar Therapeutics Inc. (Nasdaq: MNPR), a pioneering clinical-stage radiopharmaceutical company, has embarked on an exciting journey to bring innovative treatments to cancer patients. The company is making waves with its novel radiopharmaceuticals, MNPR-101-Lu and MNPR-101-Zr, designed to revolutionize cancer therapy and diagnostic imaging. This article delves into Monopar's recent advancements, emphasizing the clearance for a Phase 1 therapeutic trial of MNPR-101-Lu, the first-in-human Phase 1 trial enrollment for MNPR-101-Zr, and the recognition of their work at the upcoming European Association of Nuclear Medicine (EANM) 2024 Annual Congress.
Groundbreaking Clearance to Proceed with Phase 1 Trial of MNPR-101-Lu
On August 21, 2024, Monopar announced a significant milestone: the Human Research Ethics Committee (HREC) in Australia granted clearance to initiate a Phase 1 therapeutic trial for MNPR-101-Lu in patients with advanced cancers. This novel radiopharmaceutical combines Monopar's proprietary antibody MNPR-101, which targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177 (Lu-177). This development underscores Monopar’s commitment to advancing cancer treatment through precision medicine.
The Phase 1 trial aims to evaluate the safety, tolerability, and initial efficacy of MNPR-101-Lu in humans. Given the innovative mechanism of action, whereby the antibody selectively binds to uPAR a receptor abundantly expressed in various aggressive tumors MNPR-101-Lu holds significant potential to selectively deliver the radioactive payload to tumor cells, minimizing collateral damage to healthy tissues.
First Patient Enrolled in the Phase 1 Dosimetry and Imaging Trial of MNPR-101-Zr
Following the HREC clearance, Monopar's momentum continued with another landmark achievement. On July 9, 2024, the company announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging clinical trial of MNPR-101-Zr. This novel imaging agent is a combination of Monopar's MNPR-101 antibody and the radioisotope zirconium-89 (Zr-89).
The primary of this trial is to understand the dosimetry and biodistribution of MNPR-101-Zr in patients, hence providing crucial insights into the optimal dosing strategies and therapeutic potential of the antibody. Imaging with Zr-89 allows researchers to visualize and track the distribution of MNPR-101 within the body using positron emission tomography (PET). This information will guide the subsequent development stages of therapeutic versions of MNPR-101, such as MNPR-101-Lu.
Global Recognition at EANM 2024
Monopar’s innovative research has not gone unnoticed in the scientific community. On June 25, 2024, it was announced that an abstract
Radiopharmaceutical Revolution: Monopar Therapeutics Multi-Faceted Approach in Targeting Advanced Cancers Monopar Therapeutics Inc. (Nasdaq: MNPR), a pioneering clinical-stage radiopharmaceutical company, has embarked on an exciting journey to bring innovative treatments to cancer patients. The company is making w...
|
 Product Service News
In a significant advancement within the field of surgical medicine, Aclarion Inc. has officially launched the Clinical Utility and Economic (CLUE) Trial. This innovative study aims to assess how frequently AI-generated biomarker data from Nociscan influences surgical treatment plans formulated by surgeons. The trial will focus on the clinical relevance of Nociscan’s unique capabilities in improving patient outcomes and adjusting treatment strategies.Under the clinical protocols of the CLUE Trial, surgeons will outline their initial surgical treatment plans prior to receiving any Nociscan data. Following the analysis of the AI-generated biomarker signals, they will report on how often and to what extent their initial surgical strategies change. This trial highlights Aclarion’s commitment to enhancing surgical precision by integrating advanced artificial intelligence technology into standard medical practices. Enhanced treatment plans not only aim to improve patient outcomes but also to optimize healthcare economic efficiencies in surgical settings.
|
 Product Service News
In a pivotal moment for the electric aviation industry, Lilium (NASDAQ: LILM) has entered a significant phase of development with the successful completion of the initial stage of integration testing for the electrical power system of its innovative Lilium Jet. This milestone was announced on August 21, 2024, from t...
|
 Stocks on the Move
In a year marked by economic uncertainty and stock market volatility, Aon Plc (NYSE: AON) finds itself navigating a complex landscape. As of the year-to-date reporting, Aon shares saw a performance of 14.92%, falling slightly short of the broader market’s performance, which stood at 15.02%. This divergence raises ...
|
 Stocks on the Move
Gsi Technology Inc Struggles to Keep Pace with Market Performance, Experiences Decrease in Share ValueIn the first quarter of fiscal 2025, Gsi Technology Inc reported a decrease in earnings per share, causing concern among investors. Despite being the inventor of the Associative Processing Unit (APU), a groundbreaki...
|
|
|
|
|
